Moffitt logo

COVID-19 Update: See new visitor policy effective Jan. 3. Learn More

Clinical Trials Search

Clinical Trial 21536

Cancer Type: Multiple
Study Type: Prevention
NCT#: NCT05054218

Phase: N/A
Prinicipal Investigator: Giuliano, Anna

Call 813-745-6100
or 1-800-679-0775 Learn More

Study Title

Immunogenicity of a Third Dose of mRNA-1273 Vaccine (Moderna) Among Cancer Patients


Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose.


Primary Objectives - To evaluate immunogenicity among cancer patients to a third dose of 100 µg mRNA-1273 28 days and 6 months post-vaccination Secondary Objective - To evaluate the safety of a third dose of 100 µg mRNA-1273 administered to cancer patients up to 6 months post-third vaccine dose Exploratory Objective - In a study sub-population, to characterize the T cell response pre and post receipt of a third 100 µg mRNA-1273 vaccine dose



Therapy (NOS)


mRNA-1273 ()

Inclusion Criteria

Inclusion Criteria:

  • Is a cancer patient enrolled in the Cancer Patient Immune Response to COVID-19 Vaccine Study (MCC 21138) or who has completed the two mRNA-1273 vaccine series prior to March 31, 2021.
  • Understands, agrees, and is able to comply with the study procedures and provides written informed consent.
  • Is an adult, at least 18 years of age.
  • Has no known or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients.
  • Has not received more or less than 2 doses of mRNA-1273 vaccine.

  • Exclusion Criteria

    Exclusion Criteria:

  • Does not meet inclusion criteria

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.